drugset / Trial / NCT02928432
SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone
Phase 2
Completed
26 enrolled
Spanish National Cancer Research Centre
Fundación de investigación HM · collabInstitute of Cancer Research, United Kingdom · collabInstituto de Investigacion Biomedica de Malaga · collabUniversity of Salamanca · collab
NaSingle-groupOpen-labelTreatment
Summary
Abiraterone acetate (AA) has shown a favourable impact in overall survival, administered with prednisone to decrease the adverse event related to CYP171A suppression. Our hypothesis is that the change of prednisone to dexamethasone in CRPC patients that progress biochemically to AA + prednisone can improve the number and the length of the responses, and also improve tolerance to treatment, decreasing the adverse events associated to a moderate dosage of steroids used chronically.
Timeline
- Start
- 2013-06
- Primary completion
- 2016-09
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.5 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |